Linear IgA Dermatosis in a Child: Clinical Case
Nikolay N. Murashkin,
Alexander I. Materikin,
Roman V. Epishev,
Maria A. Leonova,
Leonid A. Opryatin,
Roman A. Ivanov,
Alena A. Savelova,
Oksana R. Katunina,
Kirill A. Kulikov,
Daniel R. Danielyan https://doi.org/10.15690/vsp.v22i5.2642
Abstract
Background. Linear IgA dermatosis is a rare autoimmune bullous disease characterized by vesiculo-bullous subepidermal lesions (affecting the skin and mucous membranes) and by linear homogeneous IgA deposition in the epidermis basal membrane.
Clinical case description. Clinical case of linear IgA dermatosis in children is presented. Clinical data assessment, histological examination of the skin biopsy (to determine the depth of bullous), immunofluorescent examination (to reveal IgA deposition in the epidermis basal membrane) are crucial for reliable disease diagnosis according to the studies. Altogether it helps to establish the final diagnosis and determine the patient's management. Dapsone is the first-line treatment for this disease, it has proven to be an effective and safe medication.
Conclusion. This case of linear IgA dermatosis is of concern due to disease severity and its rarity in clinical practice. Differential diagnosis is rather complicated and clinically requires high-tech research methods. Only immunofluorescent examination allows to diagnose linear IgA dermatosis accurately. Lesions' regression was achieved due to systemic therapy with dapsone (1.8 mg/kg/day).
Supporting agencies: Not specified
About the Authors
Nikolay N. Murashkin
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leopharma, Pfizer, AbbVie, Amryt Pharma, Celgene, Mölnlycke Health Care AB, Zeldis Pharma
Alexander I. Materikin
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Eli Lilly, Novartis, AbbVie, Amryt Pharma, Jansen, Pfizer, Celgene. Receiving fees for scientific counseling from company Mölnlycke Health Care AB
Roman V. Epishev
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Eli Lilly, Novartis, AbbVie, Amryt Pharma, Jansen, Pfizer, Celgene. Receiving fees for scientific counseling from company Mölnlycke Health Care AB
Maria A. Leonova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
Leonid A. Opryatin
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
receiving fees for scientific counseling from companies Eli Lilly, Jansen
Roman A. Ivanov
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
Alena A. Savelova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
Oksana R. Katunina
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
Kirill A. Kulikov
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
Daniel R. Danielyan
Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
References
1. Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunol Res. 2018;66(1):6–17. doi: https://doi.org/10.1007/s12026-017-8975-2
2. Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous dermatosis. Clin Dermatol. 2012;30(1):38–50. doi: https://doi.org/10.1016/j.clindermatol.2011.03.008
3. Vale ECSD, Dimatos OC, Porro AM, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: dermatitis herpetiformis and linear IgA bullous dermatosis — Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):48–55. doi: https://doi.org/10.1590/abd1806-4841.2019940208
4. Ng SY, Venning VV. Management of linear IgA disease. Dermatol Clin. 2011;29(4):629–630. doi: https://doi.org/10.1016/j.det.2011.06.014
5. Lebedeva EV, Radionova EE, Malyarenko EN, et al. A clinical case of linear IgA-dependent bullous dermatosis. Russian Journal of Clinical Dermatology and Venereology = Klinicheskaya Dermatologiya i Venerologiya. 2020;19(3):326–330. (In Russ). doi: https://doi.org/10.17116/klinderma202019031326
6. Lings K, Bygum A. Linear IgA bullous dermatosis: a retrospective study of 23 patients in Denmark. Acta Derm Venereol. 2015;95(4): 466–471. doi: https://doi.org/10.2340/00015555-1990
7. Teplyuk NP, Belousova TA, Grabovskaya OV, et al. Linear IgA-dependent bullous dermatosis. Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney. 2015;18(1):40–45. (In Russ).
8. Khlebnikova AN, Fomin KA, Bobrov MA, Zaidenov VA. Case of linear IgA dermatosis. Farmateka. 2018;(s5):73–78. (In Russ). doi: https://doi.org/10.18565/pharmateca.2018.s5.73-78
9. Genovese G, Venegoni L, Fanoni D, et al. Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients. Orphanet J Rare Dis. 2019;14(1):115. doi: https://doi.org/10.1186/s13023-019-1089-2
10. Bernett CN, Fong M, Yadlapati S, Rosario-Collazo JA. Linear IGA Dermatosis. 2022 Aug 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
11. Sakaguchi M, Bito T, Oda Y, et al. Three cases of linear IgA/igG bullous dermatosis showing IgA and IgG reactivity with multiple antigens, particularly laminin-332. JAMA Dermatol. 2013;149(11):1308–1313. doi: https://doi.org/10.1001/jamadermatol.2013.5691
12. Koga H, Prost-Squarcioni C, Iwata H, et al. Epidermolysis Bullosa Acquisita: The 2019 Update. Front Med (Lausanne). 2019;5:362. doi: https://doi.org/10.3389/fmed.2018.00362
13. Yusupovа LA, Yunusovа EI, Garaeva ZS, et al. Clinical picture, differential diagnosis and therapy of patients with lichen planus. Lechaschi Vrach. 2018;(5):30. (In Russ).
14. Egan CA, Smith EP, Taylor TB, et al. Linear IgA bullous dermatosis responsive to a gluten-free diet. Am J Gastroenterol. 2001;96(6):1927–1929. doi: https://doi.org/10.1111/j.15720241.2001.03897.x
Review
For citations:
Murashkin N.N., Materikin A.I., Epishev R.V., Leonova M.A., Opryatin L.A., Ivanov R.A., Savelova A.A., Katunina O.R., Kulikov K.A., Danielyan D.R. Linear IgA Dermatosis in a Child: Clinical Case. Current Pediatrics. 2023;22(5):464-469. (In Russ.) https://doi.org/10.15690/vsp.v22i5.2642
Views:
525
Email this article 
